Author: Vivian Xie 24th July 2026

The Asia-Pacific region has emerged as one of the world’s most dynamic markets for CDMOs, driven by technical evolution across small molecules, biologics and advanced therapies. As organisations make substantial investments in capacity, pharma CDMO operations in Asia have significantly expanded over the past decade, with the regional market’s value projected to exceed USD 75 billion by 2030, substantially outpacing established markets in North America and Europe. This expansion has benefited both multinational pharma companies and homegrown CDMO organisations, including WuXi AppTec and Samsung Biologics, letting them establish dedicated contract manufacturing facilities serving regional and global markets.

In particular, Singapore has become a manufacturing hub within the Asia-Pacific pharma ecosystem, leveraging its location, robust IP protections and sophisticated regulatory infrastructure to attract substantial international investment in its manufacturing capabilities. The city-state's biomedical manufacturing sector [1] generated approximately SGD 16.4 billion in output in 2025, and is internationally recognised by major regulatory authorities, giving Singapore’s CDMOs easy access to global markets.

What’s more, the industry has taken notice of Singapore’s up-and-coming status in the world of pharmaceutical contract manufacturing, which is why globally-recognised industry events like Pharmapack Asia [2] are establishing themselves in the region to provide new forums for this growing sector. Read on to discover more about the opportunities emerging in the region for pharma companies looking to forge new contract manufacturing partnerships, and the specialised capabilities that Singapore is best placed to serve.

The Flexibility That Sets CDMOs Apart

As they need to be able to accommodate the specifications of a range of clients and product portfolios, packaging requirements for CDMOs differ fundamentally from those of dedicated manufacturing facilities. This creates an imperative for these facilities to be flexible enough to accommodate rapid changeovers between products, incorporating multiple primary packaging formats and supporting diverse secondary packaging configurations.

Flexible primary packaging must be able to handle multiple container closure systems on common filling lines through rapid format changeovers and modular equipment configurations, including vials, prefilled syringes, cartridges and bottles. For secondary packaging, this requires capabilities for diverse labelling, serialisation and packaging configurations to meet the needs of different markets and distribution channels. This flexibility has substantial economic implications, as pharmaceutical sponsors evaluate CDMO partners based on their ability to support needs across the full product lifecycle.

Quality Assurance Frameworks in CDMO Relationships

The ultimate responsibility for meeting product quality regulations falls upon pharmaceutical sponsors, as outlined in ICH and GMP guidelines, [3] requiring robust quality agreements, oversight frameworks and audit programmes to meet international standards. Take CDMO packaging into consideration, and these quality assurance frameworks become even more complex, due to additional variables related to component qualification, serialisation accuracy and labelling compliance.

Quality agreements between pharmaceutical sponsors and CDMOs establish the contractual foundation for quality management; this defines responsibilities for raw material qualification, process validation, change control, deviation management and regulatory compliance. These agreements must address packaging-specific considerations including primary packaging component qualification protocols, secondary packaging material specifications, serialisation system validation and the interface between manufacturing and packaging operations.

The globalisation of pharmaceutical supply chains renders quality assurance measures more complex, as CDMOs frequently source packaging components from multiple suppliers across different jurisdictions. The proliferation of counterfeit packaging components, particularly for high-value products, introduces integrity risks to the supply chain requiring enhanced scrutiny over supplier audits, component authentication protocols and supply chain mapping.

Regulatory Compliance Considerations Across Asia-Pacific Markets

The Asia-Pacific’s pharma markets encompass a diverse range of regulatory frameworks, some of which are more established or technically intricate than others. This regulatory heterogeneity makes it more tricky for CDMOs who serve multiple markets, as packaging operations need to meet multiple region-specific requirements related to labelling content, language, serialisation formats and tamper-evidence features. As a result, their packaging solutions need to be flexible enough to address these diverse requirements while still maintaining a consistent process and quality standard across every market they serve.

The GMP standards of Singapore's Health Sciences Authority are substantially aligned with ICH guidelines and recognised as equivalent by the FDA and EMA. This enables Singapore-based CDMOs to manufacture products for global markets with minimal need for additional qualification, giving pharmaceutical sponsors efficient pathways to supply multiple markets. The HSA follows a risk-based approach to inspection, emphasising pharmaceutical quality systems to create a regulatory environment that encourages continuous improvement and proactive quality management.

Elsewhere in the region, China's National Medical Products Administration (NMPA) has implemented increasingly stringent GMP requirements, intensifying its inspection activities at all manufacturing facilities supplying the Chinese market. The NMPA's emphasis on data integrity, process validation and risk management has elevated quality standards across the country’s pharmaceutical manufacturing sector. CDMOs who manufacture products for the Chinese market must ensure their packaging operations comply with Chinese labelling requirements, whilst maintaining serialisation capabilities which are compatible with China's emerging track-and-trace system.

Integrating Technology, Enabling Excellence

Digital technologies and Industry 4.0 applications are transforming CDMO packaging operations to enhanced process control, oversee quality assurance in real-time and employ data analytics capabilities to improve efficiency whilst reducing quality risks. Manufacturing execution systems (MES) can allow workflows to be managed digitally, enhancing traceability and reducing documentation errors compared to paper-based systems. For multi-product CDMO facilities, MES platforms [5] enable systematic line clearance verification, automated changeover protocols and enforce product-specific parameters to reduce the risk of cross-contamination.

Serialisation and track-and-trace systems are especially critical investments for CDMOs looking to scale up their tech measures, particularly for organisations whose products need to comply with multiple regulatory frameworks. The integration of serialisation systems with MES platforms and enterprise resource planning (ERP) systems enables end-to-end traceability, providing comprehensive audit trails that support regulatory compliance and supply chain integrity.

Vision inspection systems incorporating artificial intelligence and machine learning capabilities enhance defect detection, identifying subtle packaging defects that may escape detection by conventional inspection methods. For CDMOs handling multiple products with varying packaging specifications, AI-enabled vision systems can accommodate diverse inspection requirements without extensive reprogramming or validation activities, generating data that enables root cause analysis and continuous improvement.

What to Consider When Selecting a CDMO Partner

Pharmaceutical companies evaluating new partnerships with Asia-Pacific CDMOs must assess packaging infrastructure, quality management maturity and their track record of regulatory compliance alignment. Assessing packaging capabilities should be as much of a forecast as a snapshot of current capabilities, paying attention to a partner’s investment trajectory and strategic priorities. This can reassure sponsors that their CDMO partners are looking to maintain their technological currency and capacity throughout multi-year product lifecycles. Sponsors should ensure that they see their potential partner’s technology in action, whether through site visits, technical assessments or industry platforms like Pharmapack Asia, where these capabilities can be demonstrated at a smaller scale. This curated environment lets pharmaceutical professionals conduct comparative evaluations, discuss service models and assess packaging capabilities within compressed timeframes that would otherwise be impractical through individual site visits.

Pharmapack Asia’s Singapore location is particularly valuable for pharma professionals assessing their outsourcing opportunities in the region. Its position as a regional manufacturing hub, combined with its sophisticated regulatory environment and strategic connectivity to major Asian markets, makes it an ideal venue for engaging with CDMOs and develop relationships that support both immediate partnership needs and longer-term objectives.